Month: February 2025

Release – Century Lithium Announces Positive Results From Optimization Program at Angel Island Lithium Project, Nevada

Posted on by aweinsoff@channelchek.com

Research News and Market Data on CYDVF

February 24, 2025 – Vancouver, Canada – Century Lithium Corp. (TSXV: LCE) (OTCQX: CYDVF) (Frankfurt: C1Z) (“Century Lithium” or “the Company”) is pleased to announce that the Company has completed its initial internal, non-independent review, optimization work, and studies (“Optimization Study”) related to the estimated capital (“CAPEX”) described in the NI 43-101 Technical Report on the Feasibility Study of the Clayton Valley Lithium Project (now known as Angel Island), Nevada, USA, dated April 29, 2024 (“Feasibility Study”). The Optimization Study identified potential cost reductions of up to 25% of CAPEX on its initial Phase 1 CAPEX of $1.581 billion.

Optimization Study highlights leading to the CAPEX reductions:

  • Reduced capital costs through changes in flow sheet, equipment selection and updated vendor quotes in the processing areas of filtration, Direct Lithium Extraction (“DLE”) and the chlor-alkali plant
  • Internal evaluation of the estimated engineering and construction plans to identify areas of overlap and locations within the plan where modifications of site facilities and elimination of redundancies and inefficiencies can streamline the process from mining to the planned on-site production of battery-grade lithium carbonate (“Li2CO3”)
  • Reductions in the estimated cost for on-site services resulting from the changes in processing
  • Reduction in estimated indirect costs for contingency and EPCM calculated in the Feasibility Study as a percentage of direct costs as a result of the cost reductions set out above

“We are very pleased with the outcome of the Optimization Study. These results, if confirmed by an updated Feasibility Study, will have a significant impact on the economics of Angel Island,” said Century Lithium President and CEO, Bill Willoughby. “The Company is also in the process of outlining new initiatives at Angel Island that will further unlock value for our shareholders and place Angel Island in the forefront of lithium resources under development in North America.”

“Lithium remains critical for Western independence in its energy transformation, underpinning the long-term fundamentals of the industry despite current depressed prices. We believe that with these improved economics and its advanced stage of development Angel Island has now become a key asset in the broader United States’ lithium strategy.”

Century Lithium will initiate work on an Updated Feasibility Study for Angel Island to confirm the results of the Optimization Study to the required level. Century Lithium believes that the optimizations to Angel Island’s mine plan and processing, and the sale of surplus sodium hydroxide generated in the production process, will lead to competitive estimated capital and operating costs.

Qualified Person

Todd Fayram, MMSA-QP and Senior Vice President, Metallurgy of Century Lithium is the qualified person as defined by National Instrument 43-101 and has approved the technical information in this release.

ABOUT CENTURY LITHIUM CORP.

Century Lithium Corp. is an advanced stage lithium company, focused on developing its wholly owned Angel Island project in Esmeralda County, Nevada, which hosts one of the largest sedimentary lithium deposits in the United States. The Company has utilized its patent-pending process for chloride leaching combined with Direct Lithium Extraction to make battery-grade lithium carbonate product samples from Angel Island’s lithium-bearing claystone on-site at its Demonstration Plant in Amargosa Valley, Nevada.

Angel Island is one of the few advanced lithium projects in development in the United States to provide an end-to-end process to produce battery-grade lithium carbonate for the growing electric vehicle and battery storage market. Angel Island is currently in the permitting stage for a three-phase feasibility-level production plan expected to yield an estimated life-of-mine average of 34,000 tonnes per year of lithium carbonate over a 40-year mine-life, with one of the lowest estimated operating costs for lithium projects in North America.

Century Lithium trades on both the TSX Venture Exchange under the symbol “LCE” and the OTCQX under the symbol “CYDVF”; and on the Frankfurt Stock Exchange under the symbol “C1Z”.

To learn more, please visit centurylithium.com

ON BEHALF OF CENTURY LITHIUM CORP.

WILLIAM WILLOUGHBY, PhD., PE
President & Chief Executive Officer

For further information, please contact:
Spiros Cacos | Vice President, Investor Relations
Direct: +1 604 764 1851
Toll Free: 1 800 567 8181
scacos@centurylithium.com
centurylithium.com

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THE CONTENT OF THIS NEWS RELEASE.

Cautionary Note Regarding Forward-Looking Statements

This release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” and similar expressions suggesting future outcomes or statements regarding an outlook.

Forward-looking statements relate to any matters that are not historical facts and statements of our beliefs, intentions and expectations about developments, results and events which will or may occur in the future, without limitation, statements with respect to the potential development and value of the Project and benefits associated therewith, statements with respect to the expected project economics for the Project, such as estimates of life of mine, lithium prices, production and recoveries, capital and operating costs, IRR, NPV and cash flows, any projections outlined in the Feasibility Study in respect of the Project, the permitting status of the Project and the Company’s future development plans.

These and other forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein. These risks include those described under the heading “Risk Factors” in the Company’s most recent annual information form and its other public filings, copies of which can be under the Company’s profile at www.sedarplus.com. The Company expressly disclaims any obligation to update-forward-looking information except as required by applicable law. No forward-looking statement can be guaranteed, and actual future results may vary materially. Accordingly, readers are advised not to place reliance on forward-looking statements or information. Furthermore, Mineral Resources that are not Mineral Reserves do not have demonstrated economic viability.

GDEV (GDEV) – Returning Capital To Shareholders

Posted on by slightbourne@noblecapitalmarkets.com


Monday, February 24, 2025

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Special dividend. On Friday, February 21, the company announced that its board of directors approved a nonrecurring special cash dividend of $3.31 per share. The sizeable cash dividend, payable on March 11 to shareholders of record on March 3, represented a yield of roughly 20% at the time of announcement. Furthermore, the cash dividend totals roughly $60 million and will be funded entirely through the company’s healthy cash position.

Delivering value. In our view, the special cash dividend is illustrative of the Board of Directors’ confidence in the company’s long-term outlook, strong financial position, and commitment to deliver value to shareholders. Notably, we believe the company will be able to pay out the sizeable dividend without compromising its strategic growth initiatives in player retention and quality of gameplay.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Codere Online (CDRO) – A Disciplined Growth Approach

Posted on by slightbourne@noblecapitalmarkets.com


Monday, February 24, 2025

Codere Online refers, collectively, to Codere Online Luxembourg, S.A. and its subsidiaries. Codere Online launched in 2014 as part of the renowned casino operator Codere Group. Codere Online offers online sports betting and online casino through its state-of-the art website and mobile application. Codere currently operates in its core markets of Spain, Italy, Mexico, Colombia, Panama and the City of Buenos Aires (Argentina). Codere Online’s online business is complemented by Codere Group’s physical presence throughout Latin America, forming the foundation of the leading omnichannel gaming and casino presence in the region.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Currency exchange impact. Q4 revenue of €52.6 million was roughly in line with our estimate of €55.0 million in spite of currency headwinds. Adj. EBITDA of €1.9 million was better than our estimate of €1.5 million. Notably, revenues would have been stronger if not for the depreciation of the Mexican Peso, down roughly 13.5% against the Euro. On a constant currency basis, revenue was up a strong 15% compared to reported growth of 5%.

Significant market opportunity. There appears to be a very large market opportunity for the company in Latin America, with Latin American markets expected to grow a strong 33% plus Compound Annual Revenue Growth Rate. In our view, the company likely will take a disciplined approach to entering new markets by seeking partners. We believe that such a strategy could allow the company to accelerate revenue growth while allowing adj. EBITDA growth.  


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

ACCO Brands (ACCO) – Post Call Commentary

Posted on by slightbourne@noblecapitalmarkets.com


Monday, February 24, 2025

ACCO Brands Corporation is one of the world’s largest designers, marketers and manufacturers of branded academic, consumer and business products. Our widely recognized brands include AT-A-GLANCE®, Esselte®, Five Star®, GBC®, Kensington®, Leitz®, Mead®, PowerA®, Quartet®, Rapid®, Rexel®, Swingline®, Tilibra®, and many others. Our products are sold in more than 100 countries around the world. More information about ACCO Brands, the Home of Great Brands Built by Great People, can be found at www.accobrands.com.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

An Overreaction. ACCO shares fell over 17% Friday, hitting a new 52-week low, on 4.5x normal daily volume. We believe the move to be misguided and not reflective of ongoing opportunities for the Company. We would reiterate, excluding unexpectedly negative forex, that ACCO’s 4Q24 results were in line with expectations.

Go Forward. While the operating environment remains challenging, there are green shoots of opportunity for the Company, such as the renewed back to office movement. Management is placing a primary focus on improving sales trends through a number of efforts, which, when combined with cost reduction efforts, places ACCO in position to generate substantial returns once the top line improves.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Apple to Invest $500 Billion in U.S. Economy, Including AI Server Factory in Texas

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– $500B U.S. investment includes Houston AI server factory opening 2026.
– 20,000 new jobs focused on R&D, engineering, and AI development.
– Announcement follows Trump meeting amid renewed

Apple has unveiled ambitious plans to inject $500 billion into the U.S. economy over the next four years, with a significant focus on artificial intelligence infrastructure. The technology giant announced Monday that it will partner with manufacturers to build a 250,000-square-foot AI server facility in Houston, Texas, dedicated to producing hardware for Apple Intelligence, the company’s AI personal assistant that powers iPhones, iPads, and Mac computers.

This massive investment comes at a pivotal moment for Apple as it navigates growing tensions between the U.S. and China. The announcement follows a recent meeting between Apple CEO Tim Cook and President Donald Trump, who has reintroduced tariffs on Chinese imports. With Apple historically dependent on Chinese manufacturing for its devices, this U.S.-focused investment signals a strategic pivot in its production approach.

“We are bullish on the future of American innovation, and we’re proud to build on our long-standing U.S. investments with this $500 billion commitment to our country’s future,” said Apple CEO Tim Cook in the announcement.

The Houston facility, expected to begin operations in 2026, represents just one component of Apple’s comprehensive investment strategy. The company plans to hire approximately 20,000 new employees across the United States, with positions concentrated in research and development, silicon engineering, software development, and artificial intelligence.

Apple’s investment will extend beyond direct manufacturing to include doubling its U.S. Advanced Manufacturing Fund to $10 billion, establishing a new manufacturing academy in Michigan, and expanding R&D investments in cutting-edge fields like silicon engineering. The company also emphasized its content production for Apple TV+, which currently spans 20 states.

This investment announcement arrives as Apple accelerates its push into artificial intelligence with Apple Intelligence, its AI assistant unveiled earlier this year. The Texas server facility suggests Apple is building infrastructure to support more advanced AI capabilities while keeping sensitive data processing within U.S. borders—a growing concern for tech companies handling vast amounts of user information.

Apple highlighted its substantial economic contribution to the United States, noting it has paid more than $75 billion in U.S. taxes over the past five years, including $19 billion in 2024 alone, positioning itself as one of the nation’s largest corporate taxpayers.

The investment plan represents Apple’s response to mounting pressure from the Trump administration regarding U.S. manufacturing. Earlier this month, President Trump signed an order imposing additional 10% tariffs on Chinese goods, supplementing existing tariffs of up to 25% established during his first term. These trade policies have created significant challenges for companies like Apple that rely heavily on global supply chains centered in Asia.

By committing to this historic U.S. investment, Apple appears to be strategically addressing political pressures while simultaneously building the infrastructure needed to support its AI-driven future. The company’s decision to focus on AI server manufacturing also indicates its long-term commitment to developing proprietary AI solutions rather than solely relying on third-party providers like Google or OpenAI.

Industry analysts view this investment as a significant move that could inspire other tech giants to increase their U.S. manufacturing presence. The Houston facility in particular represents a strategic choice, capitalizing on Texas’s growing reputation as a technology hub outside of traditional centers like California and New York.

As competition in AI technology intensifies among major tech companies, Apple’s substantial investment in domestic AI infrastructure suggests the company is positioning itself for a future where AI capabilities become an increasingly critical differentiator in consumer technology products.

Dow Plunges 800 Points as Market Sell-Off Escalates

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– The Dow fell 805 points, with a two-day loss exceeding 1,200 points, while the S&P 500 and Nasdaq also declined.
– Economic data signaled weaker consumer sentiment, a slowing housing market, and increased inflation concerns.
– Investors moved toward safer assets, boosting bonds and defensive stocks, while major indexes fell below key technical levels.

Stocks sold off on Friday as new U.S. economic data raised investor concerns over slowing growth and persistent inflation. The Dow Jones Industrial Average tumbled 805 points, or 1.8%, bringing its two-day losses to more than 1,200 points. The S&P 500 fell 1.6%, while the Nasdaq Composite dropped over 2% as investors moved away from equities in search of safer assets.

United Health led the Dow’s decline, plunging 7% following a Wall Street Journal report that the insurer is under investigation by the Justice Department. The stock was on track for its worst day since March 2020. Meanwhile, broader economic indicators pointed to growing uncertainty. The University of Michigan consumer sentiment index fell to 64.7 in January, a sharper decline than expected, reflecting rising inflation concerns. Additionally, the 5-year inflation outlook in the survey hit 3.5%, its highest level since 1995.

Housing market data also contributed to the negative sentiment, with existing home sales dropping more than anticipated to 4.08 million units. The U.S. services purchasing managers index (PMI) also showed signs of weakness, slipping into contraction territory for February. These factors compounded fears that economic conditions may not be as strong as previously believed.

Investors sought refuge in traditionally defensive assets. The benchmark 10-year Treasury note yield declined by 8 basis points to 4.418%, boosting bond prices. The Japanese yen also strengthened against the U.S. dollar. Defensive stocks, including Procter & Gamble, General Mills, Kraft Heinz, and Mondelez, posted gains as investors shifted toward more stable sectors.

Market weakness extended across the week, with the S&P 500 down about 1%, the Dow shedding 2%, and the Nasdaq losing 1.6%. Several factors weighed on stocks, including Walmart’s weaker-than-expected earnings guidance, which sent its stock down 3% on Friday and more than 9% for the week. Inflation concerns and losses in Palantir further pressured the market.

Technical indicators added to the cautious outlook. The Dow and Nasdaq both fell below their 50-day moving averages in afternoon trading. The Dow, down 1.8%, slipped under its 50-day average of 43,695.91 for the first time since Jan. 21, while the Nasdaq, down 2%, dropped below 19,686.10, marking its first break of that level since Feb. 12.

As investors brace for more potential volatility, the focus remains on upcoming economic data and policy developments. With inflationary pressures persisting and uncertainty surrounding future policy decisions, the market’s direction remains uncertain heading into next week.

Release – Nutriband Receives Certificate of Registration for Trademark covering Pharmaceutical and Product Research and Development

Posted on by aweinsoff@channelchek.com

Research News and Market Data on NTRB

February 21, 2025 07:00 ET 

ORLANDO, Fla., Feb. 21, 2025 (GLOBE NEWSWIRE) — Nutriband Inc. (NASDAQ: NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it received the Certificate of Registration from the United States Patent and Trademark Office (USPTO) on Feb 18, 2025, for trademark registration Number 7,692,920, covering the mark “Nutriband™.” The Trademark registration covers Goods/Services: Class: 042 Product research and development, scientific research and development; biochemical research and development; pharmaceutical research and development.

The Nutriband™ trademark is integral to the commercialization of the Company’s platform technology AVERSA which can be incorporated into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. Nutriband’s lead product under development is AVERSA™ Fentanyl, an abuse deterrent fentanyl transdermal system.

Nutriband, in partnership with Kindeva Drug Delivery, is progressing towards completing the scale-up of the commercial manufacturing process for AVERSA™ Fentanyl, the first product under the AVERSA Platform that the company intends to submit for FDA approval.

According to a market analysis report by Health Advances, AVERSA™ Fentanyl has the potential to reach peak annual U.S. sales of $80 million to $200 million. This reflects the significant impact that AVERSA™ technology could have on the market for abuse deterrent pharmaceutical products.

About AVERSA™ Technology

Nutriband’s AVERSA™ abuse deterrent transdermal technology is designed to incorporate aversive agents into transdermal patches, deterring abuse by making the experience unpleasant. This technology is especially significant for drugs like fentanyl, which have a high potential for abuse. AVERSA™ aims to ensure that these essential medications remain accessible to patients who need them while enhancing their safety profiles. The AVERSA™ technology is supported by a robust intellectual property portfolio, with patents granted in the United States and several other countries including Europe, Japan, Korea, Russia, Canada, Mexico, and Australia.

About Nutriband Inc.

Nutriband Inc. is primarily engaged in developing a portfolio of transdermal pharmaceutical products. The Company’s lead product in development is an abuse deterrent fentanyl patch that incorporates AVERSA™ technology. This technology can be integrated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company’s website is www.nutriband.com. Any material contained in or derived from the Company’s websites, or any other website is not part of this press release.

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words ‘’believes,” “anticipates,” “expects” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company’s ability to develop its proposed abuse deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company’s business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Form S-1, Form 10-K for the year ended January 31, 2024 and Forms 10-Q, and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

For more information, contact:

Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com

Celsius Acquires Alani Nutrition in $1.8 Billion Deal

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– Celsius acquires Alani Nutrition in a $1.8 billion deal, expected to close in Q2 2025.
– The merger aims to create a leading functional beverage platform, catering to growing demand for zero-sugar alternatives.
– Celsius projects $2 billion in sales post-acquisition, with $50 million in cost synergies over two years.

Celsius Holdings has announced plans to acquire Alani Nutrition in a landmark $1.8 billion deal, marking a major consolidation in the U.S. energy drink market. The agreement, expected to be finalized in the second quarter of 2025, includes a net purchase price of $1.65 billion and $150 million in tax assets.

Alani Nutrition, founded in 2018, has built a reputation as a “female-focused” brand offering functional beverages and snacks tailored to Gen Z and millennial consumers. The Kentucky-based company, previously operated by Congo Brands, produces energy drinks, protein shakes, snacks, and protein powders. The acquisition will transfer ownership from co-founders Katy and Haydn Schneider, as well as Congo Brands’ co-founders Max Clemons and Trey Steiger, to Celsius Holdings.

Celsius believes the deal will create a powerful synergy, forming a “leading better-for-you, functional lifestyle platform.” By integrating Alani Nu’s products, Celsius aims to expand its reach in the functional beverage space and tap into growing demand for zero-sugar alternatives. The company expects the merger to drive approximately $2 billion in sales, leveraging the combined distribution networks, brand awareness, and innovation capabilities of both entities.

John Fieldly, Chairman and CEO of Celsius, highlighted the strategic benefits of the acquisition, stating that it will “broaden the availability of Alani Nu’s functional products” and strengthen the company’s presence in new market segments. The transaction is projected to be accretive to cash earnings per share (EPS) within the first full year of ownership, with an estimated $50 million in cost synergies to be realized over two years post-closing.

Max Clemons of Congo Brands expressed confidence in the deal, emphasizing that Celsius will “unlock key growth opportunities” for Alani Nu, particularly in expanding its distribution and consumer engagement.

The acquisition announcement coincided with Celsius reporting its fourth-quarter and full-year financial results for 2024. The company posted annual revenue of $1.36 billion, reflecting a 3% increase over the prior year. North American sales accounted for $1.28 billion, growing by 1%, while international revenues surged 37% to $74.7 million. Despite the revenue growth, Celsius experienced a decline in profitability, with adjusted EBITDA down 13% to $255.7 million and net profit falling 36% to $145.1 million.

Industry analysts view this acquisition as a strategic move that could help Celsius regain momentum in a highly competitive market. By capitalizing on Alani Nu’s strong brand presence and consumer loyalty, Celsius aims to solidify its position as a leader in the energy and functional beverage sector. The deal also signals an increasing trend of consolidation in the market, as major players look to expand their portfolios to meet shifting consumer preferences.

As the acquisition moves forward, investors and industry watchers will closely monitor how Celsius integrates Alani Nu into its operations and whether the expected synergies materialize. If successful, the merger could serve as a blueprint for future partnerships in the rapidly evolving health and wellness beverage industry.

Release – GDEV Declares One-Time, Nonrecurring Special Cash Dividend of $3.31 Per Share

Posted on by aweinsoff@channelchek.com

Research News and Market Data on GDEV

February 21, 2025 08:00 ET 

LIMASSOL, Cyprus, Feb. 21, 2025 (GLOBE NEWSWIRE) — GDEV Inc. (Nasdaq: GDEV), an international gaming and entertainment company (“GDEV” or the “Company”), today announced that its Board of Directors has authorized and approved a one-time, nonrecurring special cash dividend of $3.31 per share, representing a yield of approximately 20% based on the volume-weighted average price of the Company’s shares for the last 30 trading days prior to today’s announcement. The special dividend is payable on March 11, 2025, to the Company’s shareholders of record as of the close of business on March 3, 2025.

This one-time special dividend, totaling approximately $60 million, will be funded from GDEV’s accumulated profits over the past few years and represents a portion of the Company’s total cash balance of approximately $153 million1 (as of Q3 2024). The Company expects to release its audited results for the 2024 financial year around the end of the first quarter of 2025.

By distributing a portion of its retained earnings, GDEV better optimizes its capital structure, reducing excess liquidity and providing for a more lean and efficient operating model. This decision reflects the Company’s commitment to disciplined capital allocation and long-term value creation. The Board’s confidence in GDEV’s financial strength underscores its proactive approach to maintaining an optimal balance between stability and growth in the volatile environment. Importantly, this special dividend is a one-time distribution and does not establish a recurring dividend program. It is not anticipated that the GDEV’s Board of Directors will declare any further dividends in the foreseeable future.

GDEV Founder, CEO, and Chairman of the Board of Directors, Andrey Fadeev, stated: “The special dividend is the first in the Company’s history since our public listing. The decision to declare a special dividend underscores our commitment to delivering value to our shareholders while maintaining a strong financial position. Our robust balance sheet enables us to return capital to shareholders without compromising our ability to invest in the Company’s long-term growth. Following this distribution, GDEV will remain debt-free with a substantial cash balance providing financial stability and the continued development of both our existing portfolio and future initiatives.”

About GDEV Inc.
GDEV is a gaming and entertainment holding company, focused on development and growth of its franchise portfolio across various genres and platforms. With a diverse range of subsidiaries including Nexters and Cubic Games, among others, GDEV strives to create games that will inspire and engage millions of players for years to come. Its franchises, such as Hero Wars, Island Hoppers, Pixel Gun 3D and others have accumulated over 550 million installs and $2.5 billion of bookings worldwide. For more information, please visit www.gdev.inc.

Contacts:

Investor Relations
Roman Safiyulin | Chief Corporate Development Officer
investor@gdev.inc

Cautionary statement regarding forward-looking statements

Certain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws. Such statements are based on current expectations that are subject to risks and uncertainties. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements.

The forward-looking statements contained in this press release are based on the Company’s current expectations and beliefs concerning future developments and their potential effects on the Company. There can be no assurance that future developments affecting the Company will be those that the Company has anticipated. Forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company’s control) or other assumptions. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of the Company’s 2023 Annual Report on Form 20-F, filed by the Company on April 29, 2024, and other documents filed by the Company from time to time with the SEC. Should one or more of these risks or uncertainties materialize, or should any of the Company’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

_______________________
1 Including the investments into high quality liquid securities.

Release – Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Posted on by aweinsoff@channelchek.com

Research News and Market Data on OCGN

February 21, 2025

PDF Version

MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and live webcast to discuss the Company’s fourth quarter and full year 2024 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 5, 2025.

Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details:

Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callers
Conference ID: 5045393
Webcast: Available on the events section of the Ocugen investor site.

A replay of the call and archived webcast will be available for approximately 45 days following the event on the Ocugen investor site.

About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on X and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:
Tiffany Hamilton
AVP, Head of Communications
Tiffany.Hamilton@ocugen.com 

Unicycive Therapeutics (UNCY) – OLC Shows Synergy With Alternative Potassium Binder

Posted on by cpereira@noblefcm.com


Friday, February 21, 2025

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Pre-Clinical Study Shows Synergy With Tenapanor. Unicycive Therapeutics announced the results of an animal model study that tested its phosphate binder, OLC, or oxylanthanum carbonate, and tenapanor, a phosphate-control drug that works through a different mechanism than the phosphate binding drugs. The results showed OLC had a greater reduction than tenapanor, and the combination of both drugs given together had synergistic effects that were better than either drug given alone.

Study Design. Tenapanor (Xphozah, from Ardelyx) is a sodium/hydrogen exchanger 3 (NHE3) inhibitor that works through paracellular absorption. It is used in patients that do not respond to phosphate binders or do not tolerate them. The study, “Combination Oxylanthanum Carbonate and Tenapanor Lowers Urinary Phosphate Excretion in Rats,” was published in the American Nephrology Society’s journal Kidney360. It compared the two drugs against a control (delivery vehicle alone) in rats receiving a high phosphorus diet.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

InPlay Oil (IPOOF) – Transformative Acquisition of Pembina Cardium Oil Assets

Posted on by cpereira@noblefcm.com


Friday, February 21, 2025

InPlay Oil is a junior oil and gas exploration and production company with operations in Alberta focused on light oil production. The company operates long-lived, low-decline properties with drilling development and enhanced oil recovery potential as well as undeveloped lands with exploration possibilities. The common shares of InPlay trade on the Toronto Stock Exchange under the symbol IPO and the OTCQX Exchange under the symbol IPOOF.

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Hans Baldau, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Strategic acquisition. InPlay Oil Corp. executed a definitive agreement to acquire light oil-focused assets from Obsidian Energy Ltd. (TSX: OBE, NYSE American: OBE) in the Pembina area of Alberta. The assets have a current production rate of approximately 10,000 barrels of oil equivalent per day (boe/d), with 68% consisting of oil and natural gas liquids (NGLs). The total purchase price is C$309 million and will consist of C$220 million in cash, C$85 million in InPlay common shares priced at C$1.55 per share, and the inclusion of InPlay’s non-operated 34.6% working interest in the Willesden Green Cardium Unit #2 oil field, which has a year-end 2023 Proved Developed Producing (PDP) value of about C$4.4 million.

Transaction highlights. The acquisition appears to offer significant synergies and benefits to InPlay’s operations. InPlay’s production is expected to more than double to 18,750 boe/d from previous guidance of 8,650-9,150. Additionally, on a per share basis, 2025 adjusted funds flow (AFF) is expected to increase to C$204 million from previous guidance of C$69-75 million. Furthermore, the nature of the assets acquired is expected to enhance operational efficiencies to InPlay’s existing Pembina asset base by increasing the scale and contributing to lower decline, higher oil-weighting, and less capital-intensive production.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Codere Online (CDRO) – Favorable Underlying Revenue Trends

Posted on by cpereira@noblefcm.com


Friday, February 21, 2025

Codere Online refers, collectively, to Codere Online Luxembourg, S.A. and its subsidiaries. Codere Online launched in 2014 as part of the renowned casino operator Codere Group. Codere Online offers online sports betting and online casino through its state-of-the art website and mobile application. Codere currently operates in its core markets of Spain, Italy, Mexico, Colombia, Panama and the City of Buenos Aires (Argentina). Codere Online’s online business is complemented by Codere Group’s physical presence throughout Latin America, forming the foundation of the leading omnichannel gaming and casino presence in the region.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Currency exchange impact. Q4 revenue of €52.6 million was roughly in line with our estimate of €55.0 million in spite of currency headwinds. Adj. EBITDA of €1.9 million was better than our estimate of €1.5 million, as illustrated in Figure #1 Q4 Results. Revenues would have been stronger if not for the depreciation of the Mexican Peso, down roughly 13.5% against the Euro. On a constant currency basis, revenue was up a strong 15% compared to reported growth of 5%.

NASDAQ extends deadline. The company’s auditor, Marcum, resigned unexpectedly in December, quickly replaced by MaloneBailey. Importantly, the company was able to present a plan to NASDAQ in its hearing on January 16 and was granted an extension until May 12 to file its 2023 annual report, the maximum extension allowed. The company intends to file within the extension deadline.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.